Gyre Therapeutics, Inc.

Equities

GYRE

US4037831033

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 03:30:00 21/06/2024 am IST			5-day change	1st Jan Change
10.66 ^USD	-1.66%		-7.55%	-58.51%

18/06	Gyre Therapeutics, Inc. Announces Publication of Liver Fibrosis in Journal of Gastroenterology and Hepatology	CI
31/05	Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy	MT

Gyre Therapeutics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023

August 14, 2023 at 03:31 pm IST

Gyre Therapeutics, Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 379.27 million compared to CNY 312.67 million a year ago. Net income was CNY 81.2 million compared to CNY 63.88 million a year ago.

Latest news about Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc. Announces Publication of Liver Fibrosis in Journal of Gastroenterology and Hepatology	19/06	CI
Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy	31/05	MT
Gyre Pharmaceuticals Receives IND Approval from China?s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension	31/05	CI
Gyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Gyre Therapeutics Insider Sold Shares Worth $323,000, According to a Recent SEC Filing	04/04	MT
Gyre Therapeutics Swings to Fiscal 2023 Net Loss, Revenue Rises	26/03	MT
Gyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Gyre Therapeutics Announces Appointment of Rodney L. Nussbaum to the Board of Directors and Member of Audit Committee	21/03	CI
Gyre Therapeutics, Inc. Announces Board Changes	20/01	CI
Gyre Therapeutics, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	13/01	CI
Gyre Therapeutics, Inc. Announces CEO Changes, Effective January 15, 2024	16/12	CI
Gyre Therapeutics, Inc. and Beijing Continent Pharmaceuticals Co., Ltd. Announce the Resignation of Charles Wu as Member of the Board of Directors. Effective on January 15, 2024	16/12	CI
Gyre Therapeutics, Inc. Announces Management Changes	31/23/31	CI
Gyre Therapeutics, Inc. Announces Management Changes	31/23/31	CI
Gyre Therapeutics, Inc. Announces CEO Changes	31/23/31	CI
Gyre Therapeutics, Inc. Announces Management Changes	31/23/31	CI
Gyre Therapeutics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	14/23/14	CI

Chart Gyre Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GYRE THERAPEUTICS, INC.	-58.51%	882M
MODERNA, INC.	+37.76%	52.5B
IQVIA HOLDINGS INC.	-7.47%	39.01B
LONZA GROUP AG	+37.72%	39.31B
ICON PUBLIC LIMITED COMPANY	+11.93%	26.2B
CELLTRION, INC.	-11.17%	26.57B
ALNYLAM PHARMACEUTICALS, INC.	+16.45%	28.2B
UNITED THERAPEUTICS CORPORATION	+45.05%	14.15B
MEDPACE HOLDINGS, INC.	+33.13%	12.62B
BIO-TECHNE CORPORATION	-3.46%	11.74B

Other Biotechnology & Medical Research